Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (January 2007)
26 slides from Pharmacopeia's investor presentation, Jan 8, 2007

Slide 1: Corporate Overview
Corporate Overview San Francisco January 2007 Discovering excellence, driving clinical success TM

Slide 2: Forward-Looking Statements
Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

Slide 3: Value Drivers - Balanced Risk
Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Leader in developing DARA – IND submitted 12/28/06 First-in-class dual-acting ARB and endothelin antagonists for kidney disease Deep pipeline of potential blockbusters 5 compounds in active c

Slide 4: Balancing Risk to Build Value
Balancing Risk to Build Value 8 Million Compound Library Largest in the Industry Integrated HTS Medicinal Chemistry Pharmacology Development GSK Wyeth Organon Cephalon Schering-Plough Bristol-Myers Squibb Unique Discovery Platform Strategic Partnerships Proprietary Programs High Value Portfolio Phar

Slide 5: Agenda for Today
Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

Slide 6: One of the Deepest Portfolios in Biotech
Angiogenesis a v b 3 / a v b 5 PS388023 Parkinson’s Adenosine A 2A PS246518 Rheumatoid/MS CCR1 PS375179 Derm/Ocular JAK3 Topical PS608504 Immuno/Inflam JAK3 PS608504 Inflammation PS873266 Respiratory PS948115 Metabolic Disease PS522501 Inflammation PS386113 Oncology PS241541 CNS PS778629 Cardiovascu

Slide 7: Partnered Pipeline Advancing
Partnered Pipeline Advancing Partnered clinical programs advancing CXCR2 antagonist for COPD Successfully completed Phase 1 Active against biomarker at 50 mg in volunteers Continued clinical development on-going p38 kinase inhibitors for RA Approaching Phase 2 Well tolerated in multiple Phase 1 tria

Slide 8: Agenda for Today
Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

Slide 9: DARA – Dual Acting Angiotensin and Endothelin Receptor Antagonist
DARA – First-in-class DARA combines the properties of two marketed cardiovascular product classes in a single compound – Avapro and Tracleer Angiotensin II (Type 1) receptor blockers (ARBs) ETA selective endothelin receptor antagonists (ERAs) DARA’s combination of these activities has the potential

Slide 10: Diabetic Kidney Disease – Medical Need
Potentially control hypertension and fibrosis associated with loss of renal function pre- and post-transplant Diabetic Kidney Disease – Medical Need Progressive disease leading to dialysis and transplant 9 million diabetic nephropathy patients in the US 10 million in Japan and Europe $17B potential

Slide 11: Resistant Hypertension – Medical Need
Worldwide in 2010 there are predicted to be 28 million patients with concomitant hypertension and diabetes Resistant Hypertension – Medical Need Hypertensives requiring 3 or more drugs to ‘control’ blood pressure ~10 million in US concomitantly receive 3 or 4 products classes 24% and 8% respectively

Slide 12: ARB + ERA = Synergistic Combination
Angiotensin II and Endothelin I Vasoconstriction Tissue proliferation and fibrosis Inflammation Preclinical Results Potent blockade of endothelin and angiotensin by oral route Potent BP lowering in predictive hypertension models (SHR and DOCA) Clinical Results – Diabetic nephropathy Improved renal h

Slide 13: PS433540 – Potent as ARB and ERA
PS433540 – Potent as ARB and ERA PS-433540 (DARA) 1.4 > 10,000 BMS-19384 > 10,000 2 Irbesartan (Avapro) Endothelin IC 50 (nm, human) Angiotensin IC 50 (nm, human) Compound Irbesartan(Avapro®) AT 1 antagonist PS-433540 (DARA) AT 1 and ET A antagonist BMS-193884 ET A antagonist Angiotensin group Endot

Slide 14: Angiotensin and Endothelin Blockade
Angiotensin and Endothelin Blockade Angiotensin II PS433540 blocks both angiotensin and endothelin in vivo after oral administration in rodents with ED 50 = 0.9, 7.6 mpk ED 50 = 0.9 mg/kg Vehicle-adjusted % Inhibition (normalized) 0 10 20 30 40 50 60 70 80 90 100 Dose (mg/kg) 0.1 1.0 10.0 100.0

Slide 15: PS433540 – Antihypertensive Activity
PS433540 reduces blood pressure more than Irbesartan (Avapro) at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity PS433540

Slide 16: Potential Treatment of Choice in Kidney Disease
Current Treatment of Renal Disease Unsatisfactory Disease progresses to dialysis and transplant despite treatment Impaired quality of life with high morbidity and mortality Emerging paradigm for better disease management ARBs approved for diabetic nephropathy Benefit demonstrated for investigational

Slide 17: DARA Development Schedule
DARA Development Schedule Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 08/15/063Q-06 Submit IND 12/28/061Q-07 ‘First in man’ dosing 1Q-07 Initiate Phase 1b hypertension study End-07 Initiate Phase 2 2H-08

Slide 18: Phase 1 Clinical Evaluation
Phase 1 Clinical Evaluation Phase 1a in Healthy Subjects Establish Safety SAD (Single Ascending Dose) – up to 7 dose levels MAD (Multiple Ascending Dose) – up to 4 dose levels Confirm Dual Activity Mechanism Angiotensin Challenge in Healthy Volunteers Endothelin Challenge in Healthy Volunteers Phase

Slide 19: Agenda for Today
Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

Slide 20: Strategic Partnerships
Strategic Partnerships Late stage optimization programs Upfront $15 million technology access fee Up to $35 million per program in milestones Double-digit royalties Builds portfolio and financial runway Pharmacopeia prosecutes Phase 1 and Phase 2 Non-dilutive tranched funding - $15 million Up to $83

Slide 21: Strategic Partnerships – Wyeth JAK3 Alliance
Strategic Partnerships Alliance to develop and commercialize JAK3 Inhibitors for Immunological and Inflammatory Diseases Upfront payment for discovery phase program - $5 million Up to $9MM in research funding over 3 years Up to $175MM in preclinical, clinical and commercialization milestones Double-

Slide 22: Agenda for Today
Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

Slide 23: Financial Summary
Financial Summary For the 9 Months Ended September 30, 2006 $13.7 million in net revenue $19.6 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $30.4 million as of December 31 st , 2005 $31.0 million as of September 30, 2006 Received $20 m

Slide 24: Stock Information
Stock Information Stock Exchange: NASDAQ Stock Symbol: PCOP Shares Outstanding (10/31/2006): 21.1 million 52- Week Range: $3.39 - $6.51 Market Capitalization (01/04/2007): ~ $95 million Enterprise Value*: ~ $40 million *Calculated on cash and liquid investments as of 09/30/2006 and financing proceed

Slide 25: Pharmacopeia Today
Pharmacopeia Today DARA IND Submitted 12/28/06 First-in-class approach to significant markets Diabetic Nephropathy Resistant Hypertension Expect to be dosing healthy subjects in 1Q-07 Partnered clinical programs advancing CXCR2 antagonist for COPD – successfully completed Phase 1 (partnered with Sch

Slide 26: Discovering excellence, driving clinical success
Discovering excellence, driving clinical success TM
Source: SEC EDGAR · 8-K filed Jan 8, 2007
More decks from Pharmacopeia Inc
Pharmacopeia — Merger or Acquisition (November 2008)34 slides · Nov 3, 2008
The Oppenheimer 19th Annual Healthcare Conference (November 2008)33 slides · Nov 3, 2008
Ligand Pharmaceuticals — Merger or Acquisition (September 2008)18 slides · Sep 24, 2008
BMO Capital Markets 7th Annual Focus on Healthcare Conference 200822 slides · Aug 5, 2008
Investor Presentation (May 2008)36 slides · May 19, 2008
Investor Presentation (May 2008)11 slides · May 16, 2008